Every 10-Q that Xtant Medical Holdings, Inc. (XTNT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XTNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XTNT filings page.
Xtant Medical Holdings, Inc. reported a sharp downturn for the quarter and six months ended June 30, 2026. Total revenue fell to $23.0 million for the quarter and $43.9 million year-to-date, decreases of 35% and 36% from 2025, driven by the Coflex/CoFix and international hardware divestitures and the loss of license and skin substitute revenue. Gross margin remained comparatively high at 57.9% for the quarter, but operating income swung to a loss after a $5.0 million write-off of a distribution exclusivity deposit to Dilon and lower volume.
The company posted a quarterly net loss of $9.4 million and a six‑month net loss of $12.5 million, versus profits in the prior-year periods, with basic EPS at ($0.07) for the quarter. Cash and restricted cash were $10.2 million, and net working capital was $34.8 million. Xtant used divestiture proceeds to reduce term debt to $10.2 million and long-term debt (excluding current) to $7.3 million, while revolving borrowings were $12.0 million. Management believes existing liquidity, operations and credit capacity can fund needs through at least August 2027, but acknowledges revenue covenant waivers and continued revenue pressure.
Xtant Medical Holdings, Inc. reported first-quarter 2026 results with revenue of $20.9 million, down 37% from $32.9 million a year earlier, and a net loss of $3.1 million versus prior-year net income of $58 thousand. The decline reflects the December 2025 divestiture of Coflex/CoFix and the international hardware business and the loss of $3.6 million of license revenue following reimbursement changes effective January 1, 2026.
Gross margin fell to 57.3% from 61.5% as scale and mix shifted away from higher-margin license revenue. Operating expenses declined, with general and administrative down 17% and sales and marketing down 27%, partly due to the divestitures, but not enough to offset the revenue decline.
The company strengthened its balance sheet: total assets decreased to $78.0 million from $94.1 million while long-term debt (excluding current portion) fell to $8.1 million from $11.0 million, aided by applying $2.8 million of divestiture proceeds to term debt. Cash and restricted cash ended the quarter at $12.2 million, and net working capital was $43.8 million. Xtant also entered an exclusive U.S. distribution agreement for the HEMOBLAST Bellows hemostatic product, paying a $5.0 million exclusivity fee after quarter-end and hiring about 20 salespeople to support this new offering.
Xtant Medical Holdings (XTNT) reported a profitable Q3 2025. Total revenue was $33.3 million, up from $27.9 million a year ago, driven by $27.8 million of product sales and $5.5 million of license revenue. Gross margin improved to 66.1% from 58.4%, and net income reached $1.3 million versus a $5.0 million loss last year.
For the nine months, revenue rose to $101.6 million from $85.8 million and net income was $4.9 million compared with a $13.3 million loss. Cash and cash equivalents were $10.4 million as of September 30, 2025, with $11.3 million drawn on the line of credit and $17.4 million of long‑term debt. Share count was 140,004,240 as of November 7, 2025.
The company received $7.5 million in non‑refundable deposits tied to the pending sale of Coflex/CoFix assets and its international hardware business and prepaid a portion of its term loan under MidCap consents. U.S. sales accounted for about 91% of revenue; bill‑and‑hold contributed $0.6 million in the quarter.
Xtant Medical Holdings reported improved operating results for the quarter ended June 30, 2025 with total revenue of $35.4 million, up 18% from the prior-year quarter, driven by higher orthobiologics sales and $5.0 million of license revenue recognized in the quarter. Gross profit rose to $24.3 million, lifting gross margin to 68.6% from 62.1% a year earlier, reflecting better sales mix, scale and lower product costs. The company posted net income of $3.55 million for the quarter, reversing a prior-year loss.
On the balance sheet, total assets increased to $103.5 million and stockholders' equity to $48.5 million. Cash and restricted cash at period end totaled $7.04 million. The company remains levered with a $22.3 million term loan (net of issuance costs) and a $12.0 million outstanding on its revolving line of credit, and it reported compliance with credit covenants. Subsequent to period end, Xtant entered agreements to sell its Coflex/CoFix U.S. business for $17.5 million (with a non-refundable $2.5 million deposit received) and Paradigm Spine GmbH for $1.7 million, both closings contingent on buyer financing and subject to customary adjustments.